Bristol-Myers Squibb stock steadies as ORM-6151 halt offsets strong Q2 results

Published on 09/18/2026 at 21:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol-Myers Squibb stock closed at USD 62.84 on the NYSE on September 17, 2026, about 8.4% below its 52-week high after a decision to halt ORM-6151. The company reported Q2 2026 revenue of USD 12.97 billion, up 5.7% year on year, and will release Q3 2026 results on October 29, 2026.

Pharmazeutisches Forschungslabor mit NYC-Skyline, Wissenschaftler bei der Arbeit — Bristol-Myers Squibb US1078421011 zeigt Wissenschaftler in modernem New Yorker Onkologie-Labor mit Stadtpanorama, Illustration mit AI erstellt.

Bristol-Myers Squibb stock (ISIN US1078421011) closed at USD 62.84 on the New York Stock Exchange on September 17, 2026, leaving the shares roughly 8.4 percent below their 52-week high of USD 68.64 and about 47.8 percent above the 52-week low of USD 42.53 as investors balance strong recent earnings against a setback in the oncology pipeline.

ORM-6151 halt reshapes pipeline risk profile

Bristol-Myers Squibb has decided to halt development of ORM-6151, a blood cancer degrader-antibody conjugate candidate licensed from Orum Therapeutics, after reviewing Phase 1 clinical data conducted in the United States, Europe and Canada, according to Chosun Biz on September 18, 2026.

The decision not only removes a potential future revenue stream for Bristol-Myers Squibb but also eliminated up to USD 80 million in contingent milestone payments for Orum Therapeutics, while leaving Orum with the USD 100 million upfront payment already received, as reported by Aju Press on September 18, 2026.

Strong Q2 2026 results underpin valuation

Against this pipeline setback, Bristol-Myers Squibb posted robust financial results in the second quarter of fiscal 2026, reporting revenue of USD 12.97 billion, up 5.7 percent year on year and beating analysts' expectations by 12.9 percent, according to TradingView in an overview dated September 18, 2026.

Earnings for Q2 2026 reached USD 3.32 billion, corresponding to a profit margin of 25.57 percent, while earnings per share of USD 2.04 exceeded a consensus estimate of USD 1.60 by USD 0.44 per share, based on data from Yahoo Finance.

For investors, the combination of mid-single-digit revenue growth and a margin above 25 percent in Q2 2026 indicates that the core portfolio continues to generate substantial cash flow even as individual pipeline assets such as ORM-6151 are reassessed.

Dividend and upcoming Q3 2026 earnings date

Income-oriented shareholders also received support from a fresh dividend declaration: Bristol-Myers Squibb's board declared a cash dividend of USD 0.63 per share on September 16, 2026, with an ex-dividend date of October 2, 2026, according to Seeking Alpha via TradingView.

Looking ahead, Bristol-Myers Squibb plans to report financial results for the third quarter of 2026 on October 29, 2026, a date confirmed in a company communication disseminated via Business Wire on September 18, 2026.

That upcoming report will give investors a clearer view of whether the strong Q2 2026 trajectory in revenue and earnings can be sustained, and how the ORM-6151 halt and other pipeline moves feed into updated guidance.

Valuation, market metrics and peer context

Market data compiled from New York Stock Exchange trading show that Bristol-Myers Squibb shares closed at USD 62.84 on September 17, 2026, a decline of USD 0.76 or 1.19 percent on the day, with after-hours trading indicating a slight uptick to USD 62.90, according to a recent quote overview on CNBC referenced in an analysis published on September 18, 2026.

As of September 18, 2026, the company has a 52-week trading range between USD 42.53 and USD 68.64 and a market capitalization of about USD 129.46 billion, placing the latest closing price roughly USD 20.31, or 47.8 percent, above the 52-week low but USD 5.80, or 8.4 percent, below the 52-week high, as reported by Morningstar and summarized in a market data overview dated September 18, 2026.

In terms of valuation versus a large-cap peer, Bristol-Myers Squibb trades on a forward price-earnings multiple of about 9.2 times and a price-sales ratio of around 2.7 times, markedly lower than AbbVie, which trades at 18.5 times forward earnings and 7.5 times sales, according to a comparative analysis published by Mitrade on September 18, 2026.

That relative discount has led some investors to frame Bristol-Myers Squibb as modestly undervalued: one widely followed narrative pegs fair value at USD 66.21 per share, about 5.3 percent above the latest close of USD 62.84, according to a valuation-focused article on Yahoo Finance dated September 18, 2026.

Upcoming trial catalysts complement earnings date

Beyond financial results, trial milestones continue to matter for Bristol-Myers Squibb's long-term story. A Phase 3 study of the investigational agent izalontamab brengitecan in combination with osimertinib versus osimertinib-based controls in first-line EGFR-mutant non-small-cell lung cancer is scheduled to start on September 30, 2026, according to a catalyst calendar compiled by BioSniper.

For investors, the juxtaposition of the ORM-6151 discontinuation and new Phase 3 trial starts underlines the diversified nature of Bristol-Myers Squibb's research pipeline, in which the loss of one candidate can be offset over time by progress in other late-stage programs.

Stock level and investor takeaway

At the latest closing price of USD 62.84 on the NYSE as of September 17, 2026, Bristol-Myers Squibb stock sits in the upper half of its 52-week range but still below the recent high, offering a yield-backed exposure to a large-cap biopharmaceutical group that has delivered Q2 2026 revenue growth of 5.7 percent and a profit margin of 25.57 percent while managing pipeline risks such as the ORM-6151 halt.